Earnings per share for the last twelve months: Greenwich LifeSciences Inc (GLSI)

GLSI (Greenwich LifeSciences Inc.) - company brandmark

Greenwich LifeSciences (GLSI) management relies on a single oncology asset with a risk of insider dominance. The rolling annual earnings per share on GURU.Markets reports -1.51, which represents the current level of the metric. Supply chain reliability is ensured by cold bio-logistics. However, ultimate success depends on the results of the final phase of breast cancer vaccine trials, provided there is sufficient capital reserve.

GLSI (Greenwich LifeSciences Inc) Net earnings per share for the last 12 months history from 07/04/2022 to 11/16/2026

Analytical breakdowns for Greenwich LifeSciences, Inc (GLSI)

- company stock exchange capitalization indicators:
Comprehensive company analysis:GLSI - Greenwich LifeSciences, Inc.
Mass-produced product of Greenwich LifeSciences Inc.

For the biotechnology sector, where Greenwich LifeSciences (GLSI) focuses on the commercialization of the GP2 vaccine following the success of the FLAMINGO-01 trials, the rolling net income per share trend serves as an indicator of financial stability. This metric is calculated as the ratio of total profit over the last 12 months to the average number of shares, allowing investors to strip out one-time effects and assess the real business efficiency per share of capital.